Skip to main content
. Author manuscript; available in PMC: 2015 Aug 18.
Published in final edited form as: AIDS. 2014 Jul 17;28(11):1673–1678. doi: 10.1097/QAD.0000000000000261

Figure 1.

Figure 1

Profile of specific antiretroviral drug resistance mutations detected among newly-diagnosed HIV-infected children under 24 months of age in Johannesburg, South Africa, exposed to at least some prevention of mother-to-child transmission (PMTCT) interventions (black bars) or unexposed to PMTCT (gray bars). Panel A displays the percent with specific mutations among those with at least one non-nucleoside reverse transcriptase inhibitor (NNRTI) mutation (n=88 PMTCT; n=18 No PMTCT) and Panel B the percent with specific mutations among those with at least one nucleoside reverse transcriptase inhibitor (NRTI) mutation (n=23 PMTCT; n=8 No PMTCT).